TABLE 1

Donor demographics, CYP2D6 genotype, and cytochrome P450 protein content in single-donor HLMs

All single-donor HLMs obtained for Sekisui Xenotech. Activity scores were assigned according to the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines (Caudle et al., 2020). Protein abundances for CYP2D6 and CYP3A4 were determined via MS/MS analysis.

Donor Product no.	Lot no.	Sex	Age (y)	CYP2D6 Genotype	CYP2D6 Activity Score	CYP2D6 (pmol/mg HLM protein)	CYP3A4 (pmol/mg HLM protein)
H0289	0710505	F	60	1/2x2*	>2.25^{^a}	11.93	71.71
H0439	0710037	F	78	1/4	1.0^{^b}	3.31	4.97
H0446	0710044	M	21	4/41	0.5^{^b}	0.80	48.85
H0455	0710053	F	37	1/4	1.0^{^b}	4.25	35.53
H0485	0710139	M	10	1/2	2.0^{^c}	4.20	2.41
H0486	0710140	F	49	4/5	0.0^{^d}	<LOQ	44.44
H0493	0710147	F	64	1/1	2.0^{^c}	7.49	34.94

F, female; LOQ, limit of quantification; M, male; No., number.
↵^a Ultrarapid metabolizer status predicted.
↵^b Intermediate metabolizer status predicted.
↵^c Normal metabolizer status predicted.
↵^d Poor metabolizer status predicted.